AQX-1125 significantly attenuated the late-phase response compared with placebo ( FEV1 4-10 h : mean difference 150 mL , 20 % ; P = 0.027 ) and significantly increased the minimum FEV1 during LAR ( mean difference 180 mL ; P = 0.014 ) .